These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1144 related articles for article (PubMed ID: 27243629)

  • 1. Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis.
    Iyengar S; Tay-Teo K; Vogler S; Beyer P; Wiktor S; de Joncheere K; Hill S
    PLoS Med; 2016 May; 13(5):e1002032. PubMed ID: 27243629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.
    Najafzadeh M; Andersson K; Shrank WH; Krumme AA; Matlin OS; Brennan T; Avorn J; Choudhry NK
    Ann Intern Med; 2015 Mar; 162(6):407-19. PubMed ID: 25775313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: A real-life observational study.
    Zeng QL; Xu GH; Zhang JY; Li W; Zhang DW; Li ZQ; Liang HX; Li CX; Yu ZJ
    J Hepatol; 2017 Jun; 66(6):1123-1129. PubMed ID: 28189754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa.
    Fraser I; Burger J; Lubbe M; Dranitsaris G; Sonderup M; Stander T
    Pharmacoeconomics; 2016 Apr; 34(4):403-17. PubMed ID: 26666639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US.
    Zhang S; Bastian ND; Griffin PM
    BMC Gastroenterol; 2015 Aug; 15():98. PubMed ID: 26239358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States.
    Chhatwal J; Kanwal F; Roberts MS; Dunn MA
    Ann Intern Med; 2015 Mar; 162(6):397-406. PubMed ID: 25775312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan.
    Kawaguchi I; Chayama K; Gonzalez YS; Virabhak S; Mitchell D; Yuen C; Kumada H
    Adv Ther; 2020 Jan; 37(1):457-476. PubMed ID: 31808054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data.
    Chen GF; Wei L; Chen J; Duan ZP; Dou XG; Xie Q; Zhang WH; Lu LG; Fan JG; Cheng J; Wang GQ; Ren H; Wang JP; Yang XX; Jia ZS; Fu QC; Wang XJ; Shang J; Zhang YX; Han Y; Du N; Shao Q; Ji D; Li F; Li B; Liu JL; Niu XX; Wang C; Wu V; Wong A; Wang YD; Hou JL; Jia JD; Zhuang H; Lau G
    PLoS One; 2016; 11(6):e0155934. PubMed ID: 27276081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection.
    Younossi ZM; Park H; Saab S; Ahmed A; Dieterich D; Gordon SC
    Aliment Pharmacol Ther; 2015 Mar; 41(6):544-63. PubMed ID: 25619871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Hepatitis C Drugs Are Very Costly And Unavailable To Many State Prisoners.
    Beckman AL; Bilinski A; Boyko R; Camp GM; Wall AT; Lim JK; Wang EA; Bruce RD; Gonsalves GS
    Health Aff (Millwood); 2016 Oct; 35(10):1893-1901. PubMed ID: 27702964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness Analysis of New HCV Treatments in Egyptian Cirrhotic and Non-Cirrhotic Patients: A Societal Perspective.
    Elsisi GH; Aburawash A; Waked E
    Value Health Reg Issues; 2017 Sep; 13():7-15. PubMed ID: 29073993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sovaldi dilemma likely to get worse.
    Carroll J
    Manag Care; 2014 Sep; 23(9):9, 12. PubMed ID: 25282860
    [No Abstract]   [Full Text] [Related]  

  • 13. Assessing the Budget Impact and Economic Outcomes of the Introduction of Daclatasvir + Asunaprevir and Sofosbuvir/Ledipasvir for the Treatment of Chronic Hepatitis C Virus Infection in Japan.
    Ward T; Webster S; Mishina S; McEwan P; Wygant G; Wang F
    Value Health Reg Issues; 2017 May; 12():1-6. PubMed ID: 28648305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment.
    Goel A; Chen Q; Chhatwal J; Aggarwal R
    J Gastroenterol Hepatol; 2018 Dec; 33(12):2029-2036. PubMed ID: 29864213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients.
    Chidi AP; Bryce CL; Donohue JM; Fine MJ; Landsittel DP; Myaskovsky L; Rogal SS; Switzer GE; Tsung A; Smith KJ
    Value Health; 2016 Jun; 19(4):326-34. PubMed ID: 27325324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling the fiscal costs and benefits of alternative treatment strategies in the United Kingdom for chronic hepatitis C.
    Connolly MP; Kotsopoulos N; Ustianowski A
    J Med Econ; 2018 Jan; 21(1):19-26. PubMed ID: 28830254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug Pricing Evolution in Hepatitis C.
    Vernaz N; Girardin F; Goossens N; Brügger U; Riguzzi M; Perrier A; Negro F
    PLoS One; 2016; 11(6):e0157098. PubMed ID: 27310294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug pricing: still a barrier to elimination of HCV.
    The Lancet Gastroenterology Hepatology
    Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):813. PubMed ID: 30507462
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost-effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: Treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis.
    Buti M; Domínguez-Hernández R; Oyagüez I; Casado MA; Esteban R
    J Viral Hepat; 2017 Sep; 24(9):750-758. PubMed ID: 28273410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring the Case for Eminent Domain of Hepatitis C Virus Treatment Patents.
    Mattingly Ii TJ; Heil EL; Hoke KS
    J Health Care Poor Underserved; 2017; 28(2):621-625. PubMed ID: 28529212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.